ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,419.61
-0.26%
Dow Jones
38,416.81
-0.60%
US Dollar vs MXN
18.60619
0.99%
Brent Oil
83.025
1.28%
Bitcoin
67,145.61
0.58%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Halozyme Therapeutics Incorporated (HALO)

  7. Halozyme Therapeutics Incorporated (HALO) Noticias

HALO Halozyme Therapeutics Incorporated

49.01
-0.61 (-1.23%)
Última actualización: 08:38:28
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Halozyme Therapeutics Incorporated HALO NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.61 -1.23% 49.01 08:38:28
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
49.095 48.96 49.37 49.62
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
13/6/202415:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/6/202415:40EDGAR2Form 144 - Report of proposed sale of securities
06/6/202407:30PRNUSHalozyme Raises Full Year 2024 Financial Guidance and..
05/6/202415:05PRNUSHalozyme Announces Issuance of New European Patent for..
04/6/202415:30PRNUSHalozyme to Participate in the Goldman Sachs 45th Annual..
22/5/202416:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/5/202415:08EDGAR2Form 144 - Report of proposed sale of securities
21/5/202415:00EDGAR2Form 144 - Report of proposed sale of securities
21/5/202406:15PRNUSHalozyme Announces Bristol Myers Squibb Received Updated..
08/5/202407:30PRNUSHalozyme to Participate in Upcoming Investor Conferences
07/5/202415:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202415:05EDGAR2Form 8-K - Current report
07/5/202415:01PRNUSHALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING..
25/4/202415:45PRNUSMahesh Krishnan Elected to Halozyme's Board of Directors
23/4/202407:30PRNUSHalozyme to Report First Quarter 2024 Financial and..
04/3/202415:13EDGAR2Form PRE 14A - Other preliminary proxy statements
28/2/202417:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202415:07EDGAR2Form 144 - Report of proposed sale of securities
27/2/202416:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202416:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202416:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202415:08EDGAR2Form 144 - Report of proposed sale of securities
27/2/202407:30PRNUSHalozyme to Participate in Upcoming Investor Conferences
20/2/202417:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202417:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202417:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202417:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202415:07EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
20/2/202415:03EDGAR2Form 8-K - Current report
20/2/202415:01PRNUSHALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL..
16/2/202416:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202416:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202416:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202415:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202415:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202415:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202405:19EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/2/202415:30PRNUSHalozyme To Report Fourth Quarter and Full Year 2023..
29/1/202415:15PRNUSHalozyme Announces Takeda Received European Commission..
23/1/202410:52EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
18/1/202415:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202407:30PRNUSHalozyme Announces argenx Received Approval in Japan for..
17/1/202415:56EDGAR2Form 144 - Report of proposed sale of securities
17/1/202407:10EDGAR2Form 8-K - Current report
16/1/202415:26EDGAR2Form 144 - Report of proposed sale of securities
16/1/202407:15PRNUSHalozyme Announces Takeda Receives FDA Approval for HYQVIA®..
16/1/202400:15PRNUSHalozyme Announces Roche Receives European Commission..
12/1/202408:25PRNUSHalozyme to Host Investor Business Forum and Long-Term..
05/1/202415:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202318:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

NASDAQ
HALO
Halozyme Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados